Non-formulary amphetamine (Dyanavel XR®) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of ADHD or ADD -AND-

1) For patients under 21 years of age:
   - Patient has documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets
   -OR-
   - Patient is already stable on the drug

2) For patients 21 years of age or older:
   - There is a documented diagnosis of ADHD or ADD on the patient’s problem list -AND-
   - Adequate trial** (7 days) of amphetamine salt combo XR (Adderall XR), unless allergy to inactive ingredient
   -AND-
   - Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansule), unless allergy to inactive ingredient
   -AND-
   - Adequate trial** (7 days) of lisdexamfetamine (Vyvanse), unless allergy to inactive ingredient
   -OR-
   - Dose change only: patient meets current criteria and is already taking the drug

** Adequate trial of a long acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.